The HIRA does not plan to disclose the first results of the benefit re-evaluation reviewed by the committee on this day. After notifying the pharmaceutical company of the results, we plan to receive objections and then disclose the results during the second review. According to HIRA and the pharmaceutical industry on the 31st, the results of this year's salary adequacy reevaluation review will be discussed as an agenda item at the committee meeting held on the 6th.

The ingredients subject to re-evaluation this year are Hyaluronic acid eye drops;
Rebamipide, Limaprost Alfadex, Loxoprofen Sodium Hydrate, Levosulpiride, and Epinastine, etc. Among these, the market size of Hyaluronic acid eye drops,